1. Home
  2. DCBO vs ADCT Comparison

DCBO vs ADCT Comparison

Compare DCBO & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Docebo Inc.

DCBO

Docebo Inc.

N/A

Current Price

$18.39

Market Cap

489.9M

Sector

N/A

ML Signal

N/A

Logo ADC Therapeutics SA

ADCT

ADC Therapeutics SA

N/A

Current Price

$4.54

Market Cap

484.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DCBO
ADCT
Founded
2016
2011
Country
Canada
Switzerland
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
489.9M
484.4M
IPO Year
2020
2019

Fundamental Metrics

Financial Performance
Metric
DCBO
ADCT
Price
$18.39
$4.54
Analyst Decision
Buy
Strong Buy
Analyst Count
9
5
Target Price
$32.00
$7.50
AVG Volume (30 Days)
278.2K
801.2K
Earning Date
01-01-0001
03-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
44.90
EPS
N/A
N/A
Revenue
N/A
$70,837,000.00
Revenue This Year
$12.54
$14.96
Revenue Next Year
$11.82
$1.06
P/E Ratio
$22.04
N/A
Revenue Growth
N/A
1.84
52 Week Low
$16.07
$1.05
52 Week High
$33.69
$4.80

Technical Indicators

Market Signals
Indicator
DCBO
ADCT
Relative Strength Index (RSI) 50.45 64.33
Support Level $18.11 $3.25
Resistance Level $20.15 $4.71
Average True Range (ATR) 0.81 0.24
MACD 0.28 0.01
Stochastic Oscillator 71.88 84.56

Price Performance

Historical Comparison
DCBO
ADCT

About DCBO Docebo Inc.

Docebo Inc is a provider of cloud-based learning management systems. The solutions provided by the company allow learning administrators to deliver scalable and flexible personalized learning experiences, from formal training to social learning to multiple internal, external, and blended audiences. The group provides an easy-to-use, configurable, and affordable learning platform with the end-to-end capabilities and critical functionality needed to train both internal and external workforces, partners, and customers. The majority of the revenue is derived from customers based in North America.

About ADCT ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Share on Social Networks: